Literature DB >> 25515935

The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis.

April N Naegeli1, Emuella Flood2, Jennifer Tucker2, Jennifer Devlen2, Emily Edson-Heredia1.   

Abstract

Plaque psoriasis (PP) and psoriatic arthritis (PsA) are autoinflammatory chronic conditions associated with skin involvement. Pruritus, or itching, is a prevalent and bothersome symptom in patients with PP and is associated with reduced health-related quality of life. The Worst Itch Numeric Rating Scale (WI-NRS) has been developed as a simple, single item with which to assess the patient-reported severity of this symptom at its most intense during the previous 24-hour period. Qualitative research was undertaken to assess the content validity of the WI-NRS. Patients with moderate to severe PP and patients with PsA were recruited from clinical sites in the USA. The qualitative research entailed two-part interviews, which began with concept elicitation to gain understanding of patients' experiences of itching, followed by cognitive debriefing of the WI-NRS to assess the instrument's understandability, clarity, and degree of appropriateness from the patient's perspective. Twelve patients with PP and 22 with PsA participated in the study. Patients reported that itching was an important and relevant symptom of their psoriatic disease. The WI-NRS was reported to be complete and easy to understand; the recall period was considered appropriate, the response scale was familiar, and, overall, the instrument was found to be appropriate for assessing itching severity. Patient responses support the content validity of the WI-NRS. The psychometric properties of the tool will be evaluated in future studies.
© 2014 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2014        PMID: 25515935     DOI: 10.1111/ijd.12645

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  12 in total

1.  [Patient perspective of pain assessment by nursing personnel : Qualitative cross-sectional study on use of the NRS].

Authors:  L Gerken; A Windisch; R Thalhammer; S Olwitz; E Fay; H Al Hussini; B Reuschenbach
Journal:  Schmerz       Date:  2017-04       Impact factor: 1.107

Review 2.  Patient-Reported Outcomes in Psoriatic Arthritis.

Authors:  Ana-Maria Orbai; Alexis Ogdie
Journal:  Rheum Dis Clin North Am       Date:  2016-03-16       Impact factor: 2.670

3.  Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model.

Authors:  Motolani E Ogunsanya; Sung Kyung Cho; Andrew Hudson; Benjamin F Chong
Journal:  Lupus       Date:  2020-09-03       Impact factor: 2.911

4.  Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus.

Authors:  M E Ogunsanya; S K Cho; A Hudson; B F Chong
Journal:  Br J Dermatol       Date:  2019-04-07       Impact factor: 9.302

5.  Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.

Authors:  Mark G Lebwohl; Leon H Kircik; Angela Y Moore; Linda Stein Gold; Zoe D Draelos; Melinda J Gooderham; Kim A Papp; Jerry Bagel; Neal Bhatia; James Q Del Rosso; Laura K Ferris; Lawrence J Green; Adelaide A Hebert; Terry Jones; Steven E Kempers; David M Pariser; Paul S Yamauchi; Matthew Zirwas; Lorne Albrecht; Alim R Devani; Mark Lomaga; Amy Feng; Scott Snyder; Patrick Burnett; Robert C Higham; David R Berk
Journal:  JAMA       Date:  2022-09-20       Impact factor: 157.335

6.  Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Authors:  A Blauvelt; K A Papp; H Sofen; M Augustin; G Yosipovitch; N Katoh; U Mrowietz; M Ohtsuki; Y Poulin; D Shrom; R Burge; K See; L Mallbris; K B Gordon
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03-31       Impact factor: 6.166

7.  The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).

Authors:  Alice B Gottlieb; Brian Kirby; Caitriona Ryan; April N Naegeli; Russel Burge; Alison Potts Bleakman; Milena D Anatchkova; Gil Yosipovitch
Journal:  Dermatol Ther (Heidelb)       Date:  2017-12-04

8.  Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Authors:  Alice B Gottlieb; Vibeke Strand; Mitsumasa Kishimoto; Philip Mease; Diamant Thaçi; Julie Birt; Chin H Lee; Catherine L Shuler; Chen-Yen Lin; Dafna D Gladman
Journal:  Rheumatology (Oxford)       Date:  2018-10-01       Impact factor: 7.580

9.  Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.

Authors:  Joe Gorelick; David Shrom; Kiran Sikand; Lisa Renda; Russel Burge; Christine Dworkin; Craig Krebsbach; Ripsi P Patel; Chitra Karki; David Rosmarin
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-19

10.  Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.

Authors:  G Yosipovitch; M Reaney; V Mastey; L Eckert; A Abbé; L Nelson; M Clark; N Williams; Z Chen; M Ardeleanu; B Akinlade; N M H Graham; G Pirozzi; H Staudinger; S Plaum; A Radin; A Gadkari
Journal:  Br J Dermatol       Date:  2019-05-01       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.